QCOR Questcor Pharmaceuticals, Inc.
- Price as of: Aug 14, 08:55 PM EDT
QCOR Stock Dividend DataAdd QCOR to Watchlist
Looking to buy or sell QCOR?
QCOR Upcoming Dividend Payouts
QCOR Dividend Yield & Stock Price History
QCOR Dividend Payout History
QCOR Daily Snapshot
- Quote Time:
- Aug 14, 08:55 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $92.17 - $94.42
- Previous Close:
- 52 Week Low / High:
- $47.71 - $97.80
- Percent Off 52 Week High:
Brought to You by Mitre Media
QCOR Dividend Growth History
Last 5 Yrs
Last 3 Yrs
QCOR Historical Annual Dividend Data & Growth
|Payout Amount||Calendar Year||Annual Growth|
QCOR Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
QCOR Company Profile
Questcor Pharmaceuticals, Inc. (QCOR) manufactures prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Acthar Gel for the treatment of the above mentioned diseases, as well as rheumatology-related conditions. In addition, QCOR offers Doral for the treatment of insomnia. The company sells its Acthar primarily to specialty pharmacies, and Doral to pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California. Most of Questcor Pharmaceuticals’ profits are derived from Acthar, and new and existing competitors to Acthar may reduce or eliminate Questcor’s commercial opportunity. Questcor Pharmaceuticals has been paying dividends since 2012 and has increased them consecutively annually since then. Questcor Pharmaceuticals pays its dividends quarterly.
Questcor Pharmaceuticals, Inc. News
Jun 26, 2014Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Apr 14, 2014Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Apr 10, 2014Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Apr 9, 2014These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Nu Skin...
Apr 7, 2014On Monday morning, it was announced that Mallinckrodt plc (MNK) has entered into an agreement with Questcor Pharmaceuticals, Inc () that will...
Today's After Hours Earnings: Avago Technologies Ltd, Chicago Bridge & Iron Company N.V., Questcor Pharmaceuticals Inc, More (AVGO, CBI, QCOR, More)Feb 25, 2014After the bell on Tuesday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings...
Goldman Sachs Initiates Coverage on Questcor Pharmaceuticals (QCOR)Sep 17, 2013Goldman Sachs reported on Tuesday that it has started coverage on Questcor Pharmaceuticals Inc (QCOR) . The firm has initiated coverage on QCOR with a "Neutral" rating and $71 price target. This price target suggests a 8% upside from the stock's current price of $65.27. An analyst from the firm noted: "We are confident in the continued growth of Acthar by expanding further in new indications, and we believe the deal for Synacthen helped ensure the sustainability of the franchise and removed a key overhang on the stock." "However, given the recent very strong run in the stock and the current valuation, we're taking a more cautious stance on risk/reward for being an aggressive buyer here. We think there are a number of factors that could cause some downward volatility in the stock, and we would be opportunistic and look for a better entry point," added the analyst. Questcor Pharmaceuticals shares were mostly flat during pre-market trading Tuesday. The stock is up 144% YTD.Expand to read the full story
Questcor Pharmaceuticals Upgraded at BofA/Merrill Lynch (QCOR)Aug 21, 2013On Wednesday, Bank of America/Merrill Lynch reported that it has raised its rating on pharmaceutical company Questcor Pharmaceuticals Inc (QCOR) . The firm has upgraded QCOR from "Neutral" to "Buy," and has given the company an $80 price target. This price target suggests a 19% upside from the stock's current price of $64.95. Analysts have upgraded the stock due to increased Acthar sales, which are driving growth. Questcor Pharmaceuticals' shares are up $3.35, or 5.16%, during pre-market trading Wednesday. The stock is up 143% YTD. The Bottom Line Shares of Questcor Pharmaceuticals Inc (QCOR) have a 1.54% yield based on Tuesday's closing price of $64.95. Questcor Pharmaceuticals Inc (QCOR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Questcor Crushes Analysts' Q2 Estimates (QCOR)Jul 30, 2013Questcor Pharmaceuticals (QCOR) beat analyst expectations after reporting for Q2 after the bell on Tuesday afternoon. With the average expectations for Questcor EPS at $1 and revenue at $168.98, the company has far exceeded these estimates. With EPS at $1.35 and revenue at $196.1 million, President and CEO Don M Bailey is looking at the increased use of Acthar as the root cause of this jump in earnings. HP Acthar Gel is a highly purified preparation of ACTH, which is used to battle the effects of multiple sclerosis, and is a growing product in Questcor's line up; the company shipped 7050 vials in the last quarter, almost 50% more than Q2 of 2012. Questcor's shares were up 89 cents, or 1.74% at the end of trading Tuesday. The company's shares are up a massive 96.3% YTD. The Bottom Line Shares of Questcor Pharmaceuticals (QCOR) have a dividend yield of 1.93% based on Tuesday's closing price of $51.91 and its annualized dividend yield of $1. Questcor Pharmaceuticals (QCOR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Questcor Adds Former Shire CEO To Board (QCOR)Jun 10, 2013Today, Questcor Pharmaceuticals Inc (QCOR) announced its newest addition to its board of directors: former CEO of Shire PLC, Angus C. Russell. Russell held his position as CEO for five years at Shire, another biopharmaceutical company, and was also an executive for ICI, Zeneca and AstraZeneca. Shares of Questcor Pharmaceuticals closed 1.14% higher during Monday's session. Year-to-date, the stock is up 39.63%. The Bottom Line Questcor Pharmaceuticals, Inc. (QCOR) has a 2.72% yield, based on Monday's closing price of $36.71. Questcor Pharmaceuticals, Inc. (QCOR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story